FindTrial
Sign In

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00189774
Enrollment
Unknown
Registered
2005-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2008-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type II, Type 2 Diabetes Mellitus

Keywords

nateglinide, pioglitazone, combination drug therapy, treatment

Brief summary

The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

Interventions

DRUGnateglinide

Sponsors

Ajinomoto USA, INC.
CollaboratorINDUSTRY
Astellas Pharma Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Type 2 diabetes mellitus under the treatment with pioglitazone

Exclusion criteria

* Patients who cannot follow the diet therapy and/or exercise therapy * Type 1 diabetes mellitus

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026